Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atai Life Sciences N.V. (ATAI)
:ATAI
RESEARCH TOOLSreports
ATAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $2.85
Previous CloseN/A
Volume1.44M
Average Volume (3M)3.63M
Market Cap
$401.57M
Enterprise Value$109.80M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Mar 27, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding193,992,870
10 Day Avg. Volume5,770,150
30 Day Avg. Volume3,626,116
Standard Deviation0.20
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1059.54
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit349.69
Enterprise Value/Ebitda-0.90
Forecast
1Y Price Target
$10.00Price Target Upside390.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 2a data supports the advancement of the AUD program, showing that BPL-003 reduced alcohol use and heavily drinking days in patients with moderate to severe AUD.
Financial PerformanceAtai Life Sciences is reaffirmed as a leader in novel neuropsychiatric treatments, particularly those with psychedelic mechanisms.
Market PositionThe partnership with Beckley positions the company as a leading player in short-acting psychedelics, enhancing its market position and strategic reach.
Bears Say
Clinical Development RiskClinical development risk tied to lead programs BPL-003, COMP360, RL-007, and VLS-01, among others.
Equity DilutionThere is a risk of shareholder dilution due to modeled equity raises of $150M-$200M to fund clinical and business development.
Price Target RevisionThe price target revision to $10 from $15 primarily reflects a lower price target on COMPASS Pathways and the removal of GRX-917 from the model.
---
Ownership Overview
33.60% Insiders
0.61% Mutual Funds
2.53% Other Institutional Investors
62.60% Public Companies and Individual Investors
ATAI FAQ
What was Atai Life Sciences N.V.’s price range in the past 12 months?
Atai Life Sciences N.V. lowest stock price was $1.03 and its highest was $2.85 in the past 12 months.
What is Atai Life Sciences N.V.’s market cap?
Atai Life Sciences N.V.’s market cap is $401.57M.
When is Atai Life Sciences N.V.’s upcoming earnings report date?
Atai Life Sciences N.V.’s upcoming earnings report date is Mar 27, 2025 which is in 34 days.
How were Atai Life Sciences N.V.’s earnings last quarter?
Atai Life Sciences N.V. released its earnings results on Nov 13, 2024. The company reported -$0.16 earnings per share for the quarter, the consensus estimate of -$0.16 by $0.
Is Atai Life Sciences N.V. overvalued?
According to Wall Street analysts Atai Life Sciences N.V.’s price is currently Undervalued.
Does Atai Life Sciences N.V. pay dividends?
Atai Life Sciences N.V. does not currently pay dividends.
What is Atai Life Sciences N.V.’s EPS estimate?
Atai Life Sciences N.V.’s EPS estimate is -0.14.
How many shares outstanding does Atai Life Sciences N.V. have?
Atai Life Sciences N.V. has 193,992,870 shares outstanding.
What happened to Atai Life Sciences N.V.’s price movement after its last earnings report?
Atai Life Sciences N.V. reported an EPS of -$0.16 in its last earnings report, expectations of -$0.16. Following the earnings report the stock price went down -7.534%.
Which hedge fund is a major shareholder of Atai Life Sciences N.V.?
Currently, no hedge funds are holding shares in ATAI
---
ATAI Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (390.20% Upside)
$10.00 (390.20% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $22.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 8.2%
Last 30 Days ▲ 8.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.49%
12-Months-Change
Fundamentals
Return on Equity
-62.43%
Trailing 12-Months
Asset Growth
-35.92%
Trailing 12-Months
Company Description
Atai Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.
---
ATAI Stock 12 Month Forecast
Average Price Target
$10.00
▲(390.20% Upside)
Technical Analysis
Best Analysts Covering ATAI
1 Year
1 Year Success Rate
10/25 ratings generated profit
1 Year Average Return
-9.36%
reiterated a buy rating 9 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -9.36% per trade.
---